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Agomelatine is an antidepressant with a novel mechanism of action. It is a melatonergic agonist for MT1
and MT2 receptors and a serotonin (5-HT2C) receptor antagonist. Agomelatine has been suggested not to
have adverse effects on sexual functions. However, the effects of chronic agomelatine administration on
reproductive functions have not been sufficiently studied in animal models. We mainly aimed to explore
the effects of agomelatine on reproductive functions in the male and female rats. For the experimental
studies, Sprague Dawley rats were used. The animals started to receive daily oral agomelatine (10 mg/kg)
on post-natal day 21. Agomelatine advanced vaginal opening in the female rats whereas it delayed
puberty onset in the male rats. Agomelatine treatment significantly decreased intromission frequencies,
which indicates a facilitator role of this antidepressant on male sexual behavior. In the forced swimming
test (FST) used for assessing antidepressant efficacy, agomelatine induced a significant decrease in
duration of immobility, and an increase in the swimming time, respectively, which confirms the anti-
depressant-like activity of agomelatine. The present findings suggest that agomelatine shows a strong
antidepressant effect in the male rats without any adverse influences on sexual behavior, and its effects
on pubertal maturation seem to show sex-dependent differences.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Antidepressants have been suggested to be divided into high
risk (selective serotonin reuptake inhibitors, serotonin-nor-
epinephrine reuptake inhibitors, tricyclic antidepressants, and
monoamine oxidase inhibitors) and low risk (agomelatine, bu-
propion, moclobemide and reboxetine) categories with regard to
propensity for antidepressant-induced sexual dysfunction (Keks
et al., 2014). Dopamine agonists were reported to facilitate sexual
behavior, and 5-HT is generally inhibitory. Norepinephrine ago-
nists have dose-dependent effects, with low doses facilitating and
high doses inhibiting sexual behavior (Hull and Dominguez, 2007).
Most of the pharmacological agents which are used in the treat-
ment of depression are known to disrupt normal sexual functiontimur).(Ferguson, 2001), which affects the patient's quality of life and
represents the main side effect that leads to the discontinuation of
treatment (Schweitzer et al., 2009). Agomelatine has been re-
ported not to cause sexual dysfunction requiring treatment (De-
myttenaere, 2011). All dose regimens of agomelatine have been
reported to be well tolerated and have no unexpected adverse
event (Kennedy et al., 2014). Understanding that there is a strong
interaction between circadian rhythm desynchronization and
mood disorders (Wirz-Justice, 2006) is another reason, which has
led to the development of agomelatine. Agomelatine is a melato-
nergic agonist for MT1 and MT2 receptors and a serotonin (5-HT)2C
receptor antagonist (de Bodinat et al., 2010). This compound was
initially investigated as a chronobiotic; however, with the dis-
covery of the 5-HT2C antagonist activity the emphasis shifted to its
anxiolytic and antidepressant effects (Arendt and Rajaratnam,
2008). The antidepressant-like activity of agomelatine has been
suggested to depend on a combination of its melatonin agonist
and 5-HT2C antagonist properties (Papp et al., 2003; Bourin et al.,
S. Canpolat et al. / European Journal of Pharmacology 770 (2016) 33–39342004). The antidepressant effect of agomelatine has been shown in
several rodent models by using well established tests such as
forced swimming test (FST) (Bourin et al., 2004) and chronic mild
stress (Papp et al., 2003). Like other antidepressants, effects of
agomelatine were principally apparent after chronic treatment.
Therefore, in the present experiment, agomelatine administration
was continued until 120 days whereas in the studies searching the
antidepressant effect of agomelatine lasted only a few weeks.
Since the use of melatonergic drugs in children and adolescents
has been a matter of concern (Hardeland, 2009), one of the main
objectives of this study was to evaluate the antidepressant effect of
long-term agomelatine treatment by using the FST in male rats.
There are a few studies on sexual side-effects of agomelatine in
the treatment of depression in humans. Agomelatine is suggested
to demonstrate favorable sexual acceptability in depressed pa-
tients and healthy volunteers (Montejo et al., 2011) and therefore
to be a good option for the treatment of depression because it
would not have adverse effects on sexual function. Abnormal
sperm parameters have been found to be associated with treat-
ment with the SSRI citalopram but no similar association with
agomelatine (Elnazer and Baldwin, 2014). The effects of agome-
latine on sexual response have not been studied sufficiently in
animal models although melatonin was previously shown to sti-
mulate male sexual behavior in rats (Drago et al., 1999; Drago and
Busa’, 2000). Therefore, the main objective of the present experi-
ment was to investigate the effects of agomelatine on sexual re-
sponse in male rats. The effects of melatonin on pubertal ma-
turation in male and female rats were also investigated as mela-
tonin is generally suggested to have an inhibitory effect on onset of
puberty.2. Materials and methods
2.1. Animals and drug administration
Prepubertal Sprague-Dawley male and female rats, aged 21
days and weighing 4072 g, were obtained from the University of
Firat Experimental Research Unit (Elazig, Turkey). The experi-
mental protocols were approved by Firat University Ethical Com-
mittee, and the rats were treated in accordance with the national
and international laws and policies on the care and use of la-
boratory animals. The animals were weaned at day 21 postpartum
and were housed under a reversed light/darkness schedule (12 h
light: 12 h darkness from 0700 h), at constant temperature
(2171 °C) and humidity (5575%) with free access to pelleted
food and tap water. Tablet form of agomelatine was used to mimic
the administration way in humans. Valdoxan tablets containing
25 mg agomelatine (Servier Industries, Wicklow Arklow/Ireland)
were obtained from the local pharmacy. The required amount of
tablets were crushed every day and suspended in saline. They
were freshly prepared on the experiment day. Agomelatine
(10 mg/kg) was orally given by gastric gavage daily at 9:00 h. Male
and female rats received agomelatine from postnatal day (pnd) 21
(weaning day) to pnd 120 and 90, respectively. The control rats
received a daily oral injection with saline in a volume of 1 ml/kg.
Along treatment, the animals were monitored daily food and
water intake and body weight gain. Preputial separation and va-
ginal opening (VO), morphological signs of the puberty in male
and female rats, respectively, were evaluated from pnd 26 to
puberty. In the female rats, sexual cycle was detected by daily
vaginal cytology after the occurence of vaginal canalization. The
experiment ended after pnd 90. On the afternoon of the first
diestrus following 90 days, the rats were sacrified. The male rats
were maintained until pnd 120 for analyzing sexual behavior and
antidepressant eficiacy.2.2. Sexual behavior test
All sexual behavioral tests were performed during the dark
phase between 13:00 h and 16:00 h in a room with night vision
camera system. An IP day/night camera system was settled in the
room where sexual behavior parameters were determined. The
camera has a 1/3 type progressive scan sensor and infrared cut
filters. It has a higher resolution (19201080) and respective
frame rate (25 fbs). It has a light sensitivity of 0.05 lx/F1.2 for color
and 0.005 lx/F.1 for white/black images. The day/night camera
automatically switches from color to black and white mode de-
pending upon avaliable light. It is dual codec and has three dif-
ferent compression standarts: JPEG, MPEG-4, MJPEG and H.264.
The sexual performance of the rats was studied in two consequtive
tests, the first pnd 90 or 91, the second pnd 105 or 106. Each rat
was placed in a rectangular observation cage (405065) made
from plexiglas. The rat was allowed to habituate for 15 min and
then a receptive female was placed in the arena. The female rats
bilaterally overiectomized three weeks before sexual behavior test
were made sexually receptive by subcutaneous injection of es-
tradiol benzoate (10 mg/rat) and progesterone (500 mg/rat) dis-
solved in 0.2 ml of sesame oil 48 and 6 h before the test session,
respectively. Estradiol benzoate and progesterone were purchased
from Sigma Chemical Co. (St. Louis, MO). Sexual behavior was re-
corded by the video-tape recording unit as described above. Each
test lasted 30 min. Rats that did not ejaculate within 30 min were
excluded from analysis. Video tape-recordings were later replayed
and analysed in slow motion. The following parameters for the
first two ejaculation series were measured: (ML) mount latency
(time between the introduction of the female into the cage and the
first mount); (IL) intromission latency (time between the in-
troduction of the female into the cage and the first intromission);
(EL) ejaculation latency (time between the first intromission and
ejaculation); (EF) ejaculation frequency (number of ejaculations in
each copulatory series); (PEI) postejaculatory interval (interval
between each ejaculation and the next copulatory act); (MF)
mount frequency (number of mounts prior to the first ejaculation);
(IF) intromission frequency (number of intromissions prior to the
first ejaculation); (copulatory effciency) intromission frequency/
intromissionþmount frequency.
2.3. Forced swimming test
The FST (Porsolt et al., 1977) is the most widely used laboratory
test for assessing the potential clinical antidepressant activity of
drugs. The modified rat FST (Detke et al., 1995) was conducted.
Chronic agomelatine-treated and vehicle-treated control rats were
subjected to the FST. Tests were carried out two times, the first pnd
92 and the second pnd 107 on the day following each sexual be-
havior test. For pretest session, rats were individually placed for
15 min into plexyglass cylinders (60 cm height, 25 cm diameter)
containing 39 cm of water at 2571 °C, so that the rat could not
reach the floor without diving. After a pretest session of 15 min,
the rat was removed, dried with a towel and returned to its cage.
The cylinders were emptied and cleaned between rats. Following
24 h after their first exposures, the FSTs were performed. Each test
was conducted for 5 min and behaviors were recorded by a vi-
deocamera placed above the cylinder for subsequent analysis. The
observer was blind to the experimental conditions being scored.
Immobility (floating), swimming and climbing were measured
(Armario et al., 1988). When rodents are forced to swim in an
inescapable situation, they typically display an immobile posture.
When the animals become immobile, that is, floating in an upright
position and making only small movements to keep their heads
above water, the total duration of immobility was scored. Im-
mobility reflects a state of “behavioral despair”. Climbing behavior
Table 1
Effects of chronic administration of agomelatine on sexual behavior in male Spra-
gue-Dawley rats – 1st test pnd 90.
Parameter Control Agomelatine P-value
1st copulation series
ML (s) 85.0746.41 33.38712.3 0.300
IL (s) 24.7579.90 44.0715.88 0.321
MF (#) 8.1372.19 15.073.38 0.110
IF (#) 27.1372.55 18.7571.91a 0.020
III (s) 9.3671.21 14.4072.39 0.081
EL (s) 450.57775.01 527.38789.07 0.528
PEI (s) 317.75729.84 403.13732.84 0.075
CE (%) 0.7970.04 0.6070.06a 0.016
2nd copulation series
ML (s) 351.0745.39 346.43763.23 0.953
IL (s) 363.0718.9 412.25734.71 0.233
MF (#) 4.6371.13 6.8671.53 0.255
IF (#) 10.5071.74 11.1371.8 0.806
EL (s) 249.13748.97 223.5744.02 0.714
PEI (s) 453.83724.48 411.8716.9 0.209
EF (#) 2.4470.53 2.3370.87 0.747
MFT (#) 18.1273.02 24.3874.21 0.248
IFT (#) 44.7572.22 35.573.09a 0.029
TCE (%) 0.7270.04 0.06170.04 0.073
Data is represented as mean7S.E.M., ML¼mount latency, IL¼ intromission latency,
MF¼mount frequency, IF¼ intromission frequency, III¼ inter-intromission interval
for the first copulatory series, EL¼ejaculation latency, PEI¼post-ejaculatory-in-
terval, CE¼copulatory efficiency, EF¼ejaculation frequency, MFT¼total mount
frequency preceding for 30-min test, IFT¼total intromission frequency for 30-min
test, TCE¼total copulatory efficiency for 30-min test.
a Po0.05 significantly different than control (Student' t test).
Table 2
Effects of chronic administration of agomelatine on sexual behavior in male Spra-
gue-Dawley rats – 2nd test pnd 105.
Parameter Control Agomelatine P-value
1st copulation series
ML (s) 49.13 720.54 69.0741.0 0.671
IL (s) 38.13717.38 27.25715.89 0.651
MF (#) 19.6376.0 7.3871.38 0.067
IF (#) 23.7572.09 14.8872.77a 0.023
III (s) 13.4471.25 13.5772.23 0.961
EL (s) 628.0767.3 381.25786.79a 0.041
PEI (s) 385.0731.65 359.0721.44 0.498
CE (%) 0.6070.06 0.6670.05 0.426
2nd copulation series
ML (s) 356.63758.40 321.75787.45 0.745
IL (s) 390.88732.44 380.0725.6 0.796
MF (#) 10.8872.67 6.3772.49 0.238
IF (#) 8.3870.71 8.6370.8 0.818
EL (s) 236.0740.90 245.88754.32 0.889
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forepaws above the surface of the water. Swimming behavior was
defined as active swimming motions (usually horizontal)
throughout the swim cylinder.
2.4. Reproductive organs collection
All animals were killed when the experiments ended after pnd
90 for female and pnd 120 for male rats. Blood was collected, and
all reproductive tissues were dissected out and weighed.
2.5. Epididymal sperm analyses
All sperm analyses were made using the methods reported in
the study of Turk et al. (2008). The sperm concentration in the
right cauda epididymal tissue was determined with a haemocyt-
ometer. Freshly isolated left cauda epididymal tissue was used for
the analysis of sperm motility. The percentage of sperm motility
was evaluated using a light microscope with a heated stage.
2.6. Hormone measurements
Serum samples were stored at 20 °C until the assays were
performed. Serum luteinizing hormone (LH) and follicle-stimu-
lating hormone (FSH) were analyzed briefly as follows. Im-
munoplates (96-well) (Nunc, Roskilde, Denmark) were coated
with rat LH or FSH. Serum samples or standards were pre-
incubated with primary antibodies and were then transferred into
coated plates for competition with antigens on the solid phase.
Plates were washed and the secondary antibody conjugated to
streptavidin peroxidase was added into each well and color was
developed using tetramethylbenzidine as the substrate. Plates
were read at an absorbance of 450 nm using a plate reader (Biotek
Synergy HT, Winooski, VT, USA). Rat LH, rat FSH, and primary
antibodies (rabbit anti-rat LH and rabbit anti-rat FSH) were ob-
tained from Dr. AF Parlow (National Institute of Diabetes and Di-
gestive and Kidney Diseases National Hormone and Peptide Pro-
gram, National Institutes of Health, USA). Secondary antibodies
(goat anti-rabbit IgG) conjugated to streptavidin peroxidase were
purchased from Sigma-Aldrich. Sensitivity of the assays was 1 ng/
ml for LH and 2 ng/ml for FSH. Inter- and intra-assay coefficient of
variation values were below 8% for both LH and FSH.
2.7. Statistical analysis
Hormonal determinations were carried out in duplicate, with a
minimal total number of 10 samples per group and values are
expressed as mean7S.E.M. Results were analyzed using Student's
t test. For all analyses, Po0.05 was considered statistically
significant.PEI (s) 421.25715.94 449.33752.13 0.683
EF (#) 2.570.19 3.070.33 0.207
MFT (#) 33.1377.91 18.8873.20 0.117
IFT (#) 35.7572.26 32.2572.9 0.357
TCE (%) 0.5570.06 0.6470.05 0.326
Data is represented as mean7S.E.M., ML¼mount latency, IL¼ intromission latency,
MF¼mount frequency, IF¼ intromission frequency, III¼ inter-intromission interval
for the first copulatory series, EL¼ejaculation latency, PEI¼post-ejaculatory-in-
terval, CE¼copulatory efficiency, EF¼ejaculation frequency, MFT¼total mount
frequency preceding for 30-min test, IFT¼total intromission frequency for 30-min
test, TCE¼total copulatory efficiency for 30-min test.
a Po0.05 significantly different than vehicle (Student' t test)3. Results
3.1. Effects of agomelatine on sexual behavior in male rats
As seen in Tables 1 and 2, the average numbers of ejaculation
were similar in the agomelatine-treated and control groups, being
2.3370.87 and 2.4470.53 in the first test session and 3.0070.33
and 2.570.19 in the second test session, respectively. Agomelatine
treatment significantly decreased intromission frequencies
(Po0.05, Table 1) in the first copulatory series in the first and
second test sessions conducted on pnd 90 and 105, respectively.
Total intromission frequency for 30-min test was also significantly
decreased in the agomelatine-treated group in the first test ses-
sion. Ejaculation latencies did not show significant changesbetween the groups in the first test session while EL1 was sig-
nificantly decreased in the rats administered with agomelatine in
the second test session (Po0.05, Table 1). Mount and intromission
latencies were not significantly different from each other between
Fig. 1. Effects of chronic agomelatine treatment (14 weeks, 10 mg/kg.d) on anti-
depressant-like activity in the rat forced swim test (FST). Values plotted are
mean7S.E.M. *Po0.05, vs. control group (Student's t test). n¼10 for each group.
Fig. 2. Effects of chronic agomelatine treatment (14 weeks, 10 mg/kg.d) on different in
(B) pubertal weights (c) serum LH and FSH levels are presented for animals treated wi
n¼10 for each group.
S. Canpolat et al. / European Journal of Pharmacology 770 (2016) 33–3936the agomelatine-treated and control groups. Agomelatine treat-
ment did not affect postejaculatory intervals. Although copulatory
efficiency was significantly decreased (Po0.05, Table 1) by ago-
melatine treatment in the first test session, there was no sig-
nificant change in the second test session. Total copulatory effi-
ciencies for 30-min test did not also show significant changes
between the groups in the first and second test sessions.
3.2. Effects of agomelatine on the forced swimming test
The values regarding effects of agomelatine on the FST are seen
in Fig. 1. Chronic administration of agomelatine induced a statis-
tically significant decreases in duration of immobility in both of
the FST tests (Po0.05). The rats treated with agomelatine spent
more time in swimming than the controls in the second FST test
(Po0.01). Swimming time was also higher in the agomelatine-
treated rats but did not reach to a statistically significant value in
the first FST test. Climbing time was statistically unchanged by
agomelatine administration although it showed a tendency to be
increased by agomelatine compared to vehicle-treated animals in
the first FST.dices of puberty onset are documented in the male rats (A) preputial separation
th vehicle and agomelatine. *Po0.05; vs. control (vehicle) group (Student's t test).
Table 3
Effects of chronic administration of agomelatine on reproductive organs in Spra-
gue-Dawley rats – pnd 90 in the female rats and pnd 120 in the male rats.
mg/100 g body weight Control Agomelatine P-value
Male
Testicle 932.3761.46 818.7746.08 0.157
Epididymis 451.6734.01 373.2724.61 0.078
Seminal vesicle 183.277.68 181.8716.90 0.942
Prostate gland 147.179.17 136.9712.72 0.521
Female
Ovary 55.971.2 70.774.2a 0.003
Uterus 139.477.1 176.676.7a 0.001
Data is represented as mean7S.E.M.
a Po0.005 significantly different than vehicle (Student's t test)
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organs
In the male rats, puberty onset was significantly delayed by
agomelatine treatment compared with the control rats (Po0.001,Fig. 3. Effects of chronic agomelatine treatment (14 weeks, 10 mg/kg.d) on different
(B) pubertal weight (c) serum LH and FSH levels are presented for animals treated with v
vaginal opening. n¼10 for each group.Fig. 2A). Pubertal weight was significantly higher in the agome-
latine-treated group compared with control rats (Po0.001,
Fig. 2B). The reproductive organ weights were not altered by
agomelatine treatment. The weights of testicle, epididymis,
seminal vesicle and prostate gland were not significantly affected
by agomelatine treatment (Table 3). The LH (4.4770.19 vs.
3.9870.28 for control group) and FSH (13.4571.09 vs.
14.5.1970.69 for control group) levels did not show any sig-
nificant changes between the groups (Fig. 2C). Cauda epididymal
sperm count was significantly lower in the agomelatine-treated
rats compared with control rats (55.0074.7 and 73.374.3106/
organ, respectively, Po0.05). Sperm motility was significantly
lower in the agomelatine-treated animals than that in the control
rats (78.371.1 and 84705% respectively, Po0.001).
Unlike in the male rats, chronic oral administration of agome-
latine to the female rats advanced VO compared with control rats
(43.170.71 days vs. 48.971.13 days for he control group, re-
spectively, Po0.001, Fig. 3A). Pubertal weight was found to be
lower (Po0.05) in the agomelatine-treated female rats compared
to control rats (Fig. 3B). Uterine weight was significantly increased
by agomelatine treatment compared with the control groupindices of puberty onset are documented in the female rats (A) vaginal opening
ehicle and agomelatine. *Po0.05, vs. control (vehicle) group, (Student's t test). VO;
S. Canpolat et al. / European Journal of Pharmacology 770 (2016) 33–3938(Po0.001,Table 3). Ovarian weight was also significantly increased
by agomelatine (Po0.01,Table 3). Serum LH (3.6670.24 vs.
3.1970.2 ng/ml for the control group) and FSH (6.4770.49 vs.
6.3670.42 ng/ml for the control group) levels were not sig-
nificantly affected by agomelatine treatment (Fig. 3C).4. Discussion
4.1. Agomelatine and sexual behavior
Although there are at least a few studies on the effects of
agomelatine on sexual function in humans, there is no study re-
garding the effects of agomelatine on sexual behavior in animal
models to date. Therefore, this is the first study to investigate
whether agomelatine has sexual side effects or not in rats. The
present results shows that agomelatine maintained the stable
character of the sexual behavior as indicated by the unchanged
number of ejaculations. This finding is consistent with the concept
that agomelatine does not cause marked sexual dysfunction in
humans (Montejo et al., 2010). Moreover, intromission frequency
was decreased in the agomelatine-treated rats, which suggests a
facilitation of male sexual behavior induced by agomelatine
treatment. So, the present results suggest that agomelatine has
pro-sexual activity in the male rats. Since agomelatine is an ago-
nist and antagonist for melatonergic receptors (MT1 and MT2) and
5-HT2C receptors, respectively, the effects of agomelatine on sexual
behavior may result from these different receptor properties. The
fact that melatonin was previously shown to stimulate male sexual
behavior in rats (Drago et al., 1999; Drago and Busa’, 2000) in-
dicates a possible role of melatonergic receptors in the pro-sexual
activity of agomelatine. The male rats treated with melatonin were
reported to have increased ejaculation frequency, decreased
mount frequency and unchanged intromission frequency, which
also suggests a facilitatory role of melatonin in sexual behavior like
agomelatine (Brotto and Gorzalka, 2000). In that study, it is sug-
gested that 5-HT2A receptor may be involved in the action me-
chanism of melatonin. Thus, serotonergic receptors to which
agomelatine and melatonin show antagonism seem to be different,
5-HT2C and 5-HT2A for agomelatine and melatonin, respectively.
Different kinds of sexual responses to agomelatine and melatonin
as indicated by ejaculation frequency may result from involvement
of different types of serotonergic receptors. Since 5-HT2C is sug-
gested to elevate ejaculatory threshold (de Jong et al., 2006),
agomelatine-dependent antagonism to 5-HT2C receptor may lead
to a decreased ejaculatory threshold without affecting the number
of ejaculations. Agomelatine (14 days) has been reported to induce
an an exitatory effect on dopamine neurons in the ventral teg-
mental area by blocking 5-HT2C receptors (Chenu et al., 2013).
Since dopamine is suggested to be facilitative to copulation (Hull
et al., 1999), agomelatine may exerts its facilitator role in sexual
behavior by modulating dopaminergic system. Agomelatine was
previously reported to have an higher affinity for 5-HT2B, which
was initially accepted not to be present in the brain, than 5-HT2C
receptors (Gobert et al., 2000). 5-HT2B receptors have been now
found to be present in the brain (Diaz et al., 2012). It has been
suggested that the effect of agomelatine on the dopaminergic ac-
tivity of ventral tegmental area (VTA) is enhanced when 5-HT2B
receptors, which may also produce an inhibitory effect on ejacu-
lation (Yonezawa et al., 2008), are blocked by agomelatine (Chenu
et al., 2014). Sleep loss has been suggested to promote marked
changes in the male reproductive system of rats (Alvarenga et al.,
2015). Therefore, agomelatine is likely to find many applications in
sleep loss-induced sexual disorders because of its chronobiotic
effect.4.2. Effects of agomelatine on the forced swimming test
Despite the fact that chronic administration for the treatment of
depression is needed to produce clinical effects, there is no study
comparing the effects of chronic agomelatine treatment more than
4 weeks on behaviors in the FST in animal models. In the present
experiment, agomelatine treatment continued from pnd 21 to pnd 120
about 14 weeks compared to a few weeks in the literature. Thus, this
long term treatment has included both adolescence and adult periods.
The present study indicates that chronic agomelatine treatment pro-
duces an anti-immobility activity in the FST in male rats. Like a wide
range of antidepressant treatments (Cryan andMombereau, 2004), the
agomelatine-treated rats decreased significantly duration of im-
mobility compared to the vehicle-treated rats in the test. Our findings
are consistent with the previous studies showing decreased im-
mobility following 22 day agomelatine treatment with a dose of
40 mg/kg i.p. (Ladurelle et al., 2012) and 13 day agomelatine treatment
with the doses of 2, 10, 50 mg/kg p.o. (Bourin et al., 2004). In addition
to immobility time in the FST in rats, there is only one agomelatine
study (Ladurelle et al., 2012) looking at swimming and climbing be-
havior, which do not show statistically significant differences in the
agomelatine-treated rats and control animals. In the current experi-
ment, swimming time was significantly increased by chronic agome-
latine treatment but climbing time remained unchanged despite
showing a tendency to increase. Swimming behavior and climbing
behavior are reported to be increased by serotonergic and nora-
drenergic antidepressants in rats, respectively (Cryan et al., 2005).
Thus, the present findings suggest that agomelatine exerts an anti-
immobility effect similar to that of SSRI in the FST. It is also concluded
that agomelatine shows a stronger anti-immobility activity in the FST
when chronically performed. Although, the previous studies suggest
that the efficacy of agomelatine in the FST involves a combination of
both its melatonin agonist and 5-HT2C receptor antagonist properties
(Bourin et al., 2004), their contribution ratios to antidepressant effect
remain obscure. The antidepressant-like effects of agonist activity of
agomelatine on melatonergic receptors are consistent with data re-
porting that melatonin reduced immobility times (Shaji and Kulkarni,
1998) but conflict with data showing that the rats treated with mel-
atonin spent less time swimming and more time climbing (struggling)
without no alteration in immobility behavior (Brotto et al., 2000).
4.3. Effects of agomelatine on reproductive functions
It has been demonstrated that melatonin treatment in children can
be sustained over a long period of time without substantial deviation
of the development of children with respect to puberty development
(van Geijlswijk et al., 2011). Interestingly, agomelatine treatment from
weaning had different effects on puberty onset in the female and male
rats in our study. Agomelatine administration advanced puberty in the
female rats while causing a delay in the male rats. Melatonin is gen-
erally accepted to have a puberty-delaying effect as the melatonin
levels decrease considerably near puberty (de Holanda et al., 2011).
Our previous study indicated that melatonin had a direct effect on
immortalized GnRH GT1-7 cells (Kelestimur et al., 2012). The present
finding that agomelatine advanced puberty onset in the female rats is
not consistent with the results of the studies suggesting a puberty-
delaying effect of melatonin. Therefore, there must be a mechanism by
which agomelatine exerts its effect rather than centrally. Agomelatine
treatment caused a reverse effect on puberty onset in the male rats
compared to the female rats. Puberty onset was significantly delayed
in the agomelatine-treated male rats. Melatonin is suggested to have
an inhibitory role in Leydig cell steroidogenesis (Frungieri et al., 2005).
Therefore, local effects of melatonin on testes may be responsible for
its puberty-delaying effect.
One of the most interesting finding in the current experiment
was that long-term administration of agomelatine caused
S. Canpolat et al. / European Journal of Pharmacology 770 (2016) 33–39 39significant decreases in sperm count and motility. Since agome-
latine has been reported to increase serum prolactin level (Tan,
2013), the decrease in spermatogenesis may result from the
changes in the prolactin secretion. The changes in sperm quality
resulting from chronic agomelatine treatment do not seem to
impair fertilization process (Cooper et al., 2010). Further studies
looking at the effects of agomelatine on human sperm quality
should be carried out as agomelatine has been suggested not to
have any effect on semen quality (Elnazer and Baldwin, 2014),
which is a case report including only one patient.
In conclusion, chronic treatment with agomelatine does not
lead to adverse effects on sexual behavior and even exerts some
putative pro-sexual effects in adult male rats. To our knowledge,
this study provides the first evidence of lack of sexual dysfunction
by chronic agomelatine treatment in rats. Our work also shows
that agomelatine induces an antidepressant-like effect by means
of enhancement of serotonergic and possible dopaminergic ac-
tivity. Further studies are needed to explore whether agomelatine
shows an antidepressant-like effect without sexual dysfunction in
female rats. Finally, as our data suggest that the effects of chronic
agomelatine administration on reproductive seem to be sex-de-
pendent, clinical use of agomelatine may lead to different side-
effects in male and female. The understanding of the effects of
agomelatine will not only contribute to the delination of the
combination of melatonergic and 5-HT2C receptor activation in the
treatment of depression, but may also provide new therapeutic
approaches to treat some reproductive disorders.Acknowledgments
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